Pfizer (PFE) announced that the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practice voted to expand its recommendation for the use of certain pneumococcal vaccines, including Prevnar 20 for all adults aged 50 and older. This recommendation is pending final approval by the director of the CDC and the Department of Health and Human Services. With respect to Prevnar 20, ACIP recommended: Vaccination is recommended for all adults aged greater than or equal to50 years and for adults aged 19-49 years with certain underlying conditions or risk factors who have not received a PCV or whose vaccination history is unknown.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Activist Starboard Accuses Pfizer’s (PFE) Executives of $20B Value Erosion
- Pfizer announces FDA approval of Abrysvo
- Starboard urges Pfizer board to ‘hold management accountable’, FT reports
- GE Aerospace, GM report quarterly earnings beats: Morning Buzz
- Pfizer, Lilly pressed about telehealth prescriber relationships, STAT reports